comparemela.com

Klaus Giese News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Evaxion and Pantherna announce promising preclinical mRNA vaccine dataCOPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-p.

New yorkUnited statesKlaus gieseHertz mortensenBrandenburg innovationsforumGerrit maassPantherna therapeutics gmbhNasdaq new york

Investegate |Evaxion Biotech Announcements | Evaxion Biotech: Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Investegate announcements from Evaxion Biotech, Evaxion and Pantherna announce promising preclinical mRNA vaccine data

New yorkUnited statesKlaus gieseHertz mortensenBrandenburg innovationsforumGerrit maassExchange commissionSecurities exchangePantherna therapeutics gmbhNasdaq new yorkSecurities actSecurities exchange actAnnual reportInvestegate announcementsInvestegate company announcementsEvaxion biotech

Evaxion Biotech: Evaxion and Pantherna announce promising preclinical mRNA vaccine data

COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the

New yorkUnited statesKlaus gieseHertz mortensenSchwierige zeitenGerrit maassExchange commissionSecurities exchangePantherna therapeutics gmbhNasdaq new yorkSecurities actSecurities exchange actAnnual report

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,.

Kenji yasukawaKlaus gieseTaiji sawamotoBrandenburg innovationsforumAstellas pharma incResearch operationsDrug developmentAstellas pharmaPantherna therapeutics gmbhChief executive officerExecutive vice presidentApplied researchFocus areaFocus area approachTrend honorInnovative product

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,.

Kenji yasukawaKlaus gieseTaiji sawamotoBrandenburg innovationsforumAstellas pharma incResearch operationsDrug developmentAstellas pharmaPantherna therapeutics gmbhChief executive officerExecutive vice presidentApplied researchFocus areaFocus area approachTrend honorInnovative product

vimarsana © 2020. All Rights Reserved.